| Pair Name | Triptolide, Gefitinib | ||
| Phytochemical Name | Triptolide (PubChem CID: 107985 ) | ||
| Anticancer drug Name | Gefitinib (PubChem CID: 123631 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Triptolide, Gefitinib | |||
| Disease Info | [ICD-11: 2C25.Z] | Lung cancer | Investigative | |
| Biological Phenomena | Inhibition-->Epithelial-mesenchymal transition | |||
| Gene Regulation | Up-regulation | Expression | CDH1 | hsa999 |
| Down-regulation | Expression | MMP9 | hsa4318 | |
| Down-regulation | Expression | SNAI1 | hsa6615 | |
| Down-regulation | Expression | VIM | hsa7431 | |
| In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
| Result | The present results indicated that the combination of TP and TKIs may be a promising therapeutic strategy to treat patients with NSCLCs harboring EGFR mutations. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Triptolide inhibits epithelial‑mesenchymal transition and induces apoptosis in gefitinib‑resistant lung cancer cells. Oncol Rep. 2020 May;43(5):1569-1579. doi: 10.3892/or.2020.7542. | Click |
